🧬 A new discovery explains why weight-loss drugs such as Ozempic and Wegovy lose effectiveness over time
In an important scientific step, researchers at the National Institutes of Health (NIH) revealed mechanisms inside brain cells that explain how weight-loss drugs that rely on GLP-1 receptors, including semaglutide used in drugs such as Ozempic and Wegovy, affect appetite and weight loss, and why their effectiveness declines over time.
These findings come after in-depth studies focused on mice to uncover the molecular details inside neurons, opening the door to a better understanding that explains individual differences in patients’ responses to these drugs.
🧠 How do GLP-1 drugs work on the brain?
GLP-1 receptor drugs are known for their role in reducing appetite and promoting weight loss by affecting brain regions that control appetite.
More importantly, while previous studies focused on identifying these areas in the brain, the current study conducted an innovative experiment using fluorescence imaging to monitor the effect of semaglutide on live mouse brain tissue, with a focus on activity inside the neurons themselves.
Using techniques to block or remove specific signaling molecules inside cells, the scientists were able to identify the cellular pathways responsible for weight-loss effects.
Importance of the cAMP molecule in neural performance
The experiments showed that the effect of semaglutide depends strongly on increasing levels of cyclic adenosine monophosphate (cAMP) in the area postrema, a part of the brain that controls appetite regulation.
However, the neuronal response was not uniform, as variation in cAMP levels was observed between cells, with the response being gradual rather than following an “all or nothing” pattern.
🧪 Why does the effectiveness of GLP-1 drugs decline over time?
This decline was explained by observing the behavior of neurons while semaglutide was present in them, where researchers found that some cells maintain elevated cAMP levels for long periods, while other cells show only a temporary increase.
The results indicate that some cells may reduce their response through mechanisms such as internalization or degradation of GLP-1 receptors, leading to a decrease in effect over time.
A strategy to prolong effectiveness
The team also tested the effect of another drug called roflumilast, which works by inhibiting the PDE4 enzyme responsible for breaking down cAMP.
Inhibiting PDE4 led to shifting more neurons toward a long-term response, meaning it may be possible to keep the effect of GLP-1 drugs stronger for longer periods.
- Increase the neural effectiveness of semaglutide
- Reduce the need for frequent repeated doses
- Avoid the phenomenon of weight-loss plateau that some patients experience
🩺 Future challenges and research prospects
Despite the notable progress, the study relied on monitoring signaling processes within brain tissue over a short time period of only hours, which limits the ability to track drug effects over longer periods measured in days or weeks.
The researchers plan to use advanced techniques that may allow these processes to be monitored for longer periods, enabling them to investigate more precisely how the brain adapts to GLP-1 drugs over time.
These findings represent an important step in understanding the neurochemical structure targeted by GLP-1 receptor drugs, and they may support the development of innovative, effective, and sustainable treatment strategies for dealing with obesity and weight-related issues.
🌱 Conclusion
NIH scientists deeply studied how GLP-1 drugs such as Ozempic and Wegovy affect neurons in the brain, and the importance of the cAMP molecule in the appetite-regulating region and its varying effect between cells became clear.
The results showed that the variation in cell response through modifying GLP-1 receptors is a major reason these drugs stop working effectively over time.
The experiment using roflumilast also showed the possibility of enhancing the response of these cells for longer periods, which may help improve weight-loss outcomes and reduce the need for repeated doses.
Overall, this research opens new doors to understanding GLP-1-based treatment protocols and how to develop them so they are better able to preserve health benefits in the long term.
📚 Related articles
Discover more from Mohdbali
Subscribe to get the latest posts sent to your email.
